Prognostic immune-related gene models for breast cancer: a pooled analysis

References

• PerouCMSorlieTEisenMBMolecular portraits of human breast tumoursNature2000406679774775210963602
   PubMed Web of Science ®Google Scholar
• GoldhirschAWinerEPCoatesASPersonalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Ann Oncol20132492206222323917950
   PubMed Web of Science ®Google Scholar
• CoatesASWinerEPGoldhirschATailoring therapies–improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Ann Oncol20152681533154625939896
   PubMed Web of Science ®Google Scholar
• SotiriouCNeoSYMcShaneLMBreast cancer classification and prognosis based on gene expression profiles from a population-based studyProc Natl Acad Sci U S A200310018103931039812917485
   PubMed Web of Science ®Google Scholar
• PaikSTangGShakSGene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancerJ Clin Oncol200624233726373416720680
   PubMed Web of Science ®Google Scholar
• AlbainKSBarlowWEShakSPrognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trialLancet Oncol2010111556520005174
   PubMed Web of Science ®Google Scholar
• PaikSShakSTangGA multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancerN Engl J Med2004351272817282615591335
   PubMed Web of Science ®Google Scholar
• ParkerJSMullinsMCheangMCSupervised risk predictor of breast cancer based on intrinsic subtypesJ Clin Oncol20092781160116719204204
   PubMed Web of Science ®Google Scholar
• PratACheangMCMartinMPrognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancerJ Clin Oncol201331220320923233704
   PubMed Web of Science ®Google Scholar
• MartinMPratARodriguez-LescureAPAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancerBreast Cancer Res Treat2013138245746623423445
   PubMedGoogle Scholar
• FilipitsMNielsenTORudasMThe PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancerClin Cancer Res20142051298130524520097
   PubMed Web of Science ®Google Scholar
• ScottEMamawalaMEpsteinJIIntermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer Tosoian JJ, Mamawala M, Epstein JI, Landis P, Wolf S, Trock BJ, Carter HB. J Clin Oncol. 20;33(30):3379–3385. [Epub 2015 Aug 31]. doi:10.1200/JCO.2015.62.5764Urol Oncol2017353121122
   Google Scholar
• SestakIDowsettMZabagloLFactors predicting late recurrence for estrogen receptor-positive breast cancerJ Natl Cancer Inst2013105191504151124029245
   PubMedGoogle Scholar
• AaldersKCKuijerAStraverMECharacterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trialEur J Cancer2017799810528477490
   PubMedGoogle Scholar
• CardosoFvan’t VeerLJBogaertsJ70-Gene signature as an aid to treatment decisions in early-stage breast cancerN Engl J Med2016375871772927557300
   PubMed Web of Science ®Google Scholar
• MakamaMDrukkerCARutgersEJAn association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint®)Eur J Cancer20177551328214658
   PubMedGoogle Scholar
• SestakIZhangYSchroederBECross-stratification and differential risk by breast cancer index and recurrence score in women with hormone receptor-positive lymph node-negative early-stage breast cancerClin Cancer Res201622205043504827252417
   PubMedGoogle Scholar
• SgroiDCChapmanJABadovinac-CrnjevicTAssessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 studyBreast Cancer Res2016181126728744
   PubMedGoogle Scholar
• SgroiDCSestakICuzickJPrediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study populationLancet Oncol201314111067107624035531
   PubMed Web of Science ®Google Scholar
• MathieuMCMazouniCKestyNCBreast Cancer Index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapyAnn Oncol20122382046205222112967
   PubMedGoogle Scholar
• PusztaiLGene expression profiling of breast cancerBreast Cancer Res200911Suppl 3S1120030862
   PubMedGoogle Scholar
• CheangMCChiaSKVoducDKi67 index, HER2 status, and prognosis of patients with luminal B breast cancerJ Natl Cancer Inst20091011073675019436038
   PubMed Web of Science ®Google Scholar
• WirapatiPSotiriouCKunkelSMeta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signaturesBreast Cancer Res2008104R6518662380
   PubMedGoogle Scholar
• DesmedtCHaibe-KainsBWirapatiPBiological processes associated with breast cancer clinical outcome depend on the molecular subtypesClin Cancer Res200814165158516518698033
   PubMed Web of Science ®Google Scholar
• TeschendorffAEMiremadiAPinderSEEllisIOCaldasCAn immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancerGenome Biol200788R15717683518
   PubMed Web of Science ®Google Scholar
• TeschendorffAEGomezSArenasAImproved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modulesBMC Cancer20101060421050467
   PubMed Web of Science ®Google Scholar
• OhEChoiYLParkTLeeSNamSJShinYKA prognostic model for lymph node-negative breast cancer patients based on the integration of proliferation and immunityBreast Cancer Res Treat2012132249950921667120
   PubMedGoogle Scholar
• BianchiniGIwamotoTQiYPrognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancerCancer Res201070218852886220959472
   PubMed Web of Science ®Google Scholar
• NagallaSChouJWWillinghamMCInteractions between immunity, proliferation and molecular subtype in breast cancer prognosisGenome Biol2013144R3423618380
   PubMed Web of Science ®Google Scholar
• YauCEssermanLMooreDHWaldmanFSninskyJBenzCCA multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancerBreast Cancer Res2010125R8520946665
   PubMed Web of Science ®Google Scholar
• Ursini-SiegelJCorySZuoDReceptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune responseCancer Res201070207776778720924104
   PubMedGoogle Scholar
• ChengWYOu YangTHAnastassiouDDevelopment of a prognostic model for breast cancer survival in an open challenge environmentSci Transl Med20135181181ra150
   Web of Science ®Google Scholar
• IgnatiadisMSinghalSKDesmedtCGene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysisJ Clin Oncol201230161996200422508827
   PubMed Web of Science ®Google Scholar
• UnoHCaiTXTianLWeiLJEvaluating prediction rules for t-year survivors with censored regression modelsJ Am Stat Assoc2007102478527537
   Web of Science ®Google Scholar
• AlexeGDalginGSScanfeldDHigh expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence ratesCancer Res20076722106691067618006808
   PubMed Web of Science ®Google Scholar
• SchmidtMBohmDvon TorneCThe humoral immune system has a key prognostic impact in node-negative breast cancerCancer Res200868135405541318593943
   PubMed Web of Science ®Google Scholar
• BianchiniGQiYAlvarezRHMolecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancersJ Clin Oncol201028284316432320805453
   PubMed Web of Science ®Google Scholar
• PerezEAThompsonEABallmanKVGenomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab TrialJ Clin Oncol201533770170825605861
   PubMedGoogle Scholar
• LoiSMichielsSSalgadoRTumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trialAnn Oncol20142581544155024608200
   PubMed Web of Science ®Google Scholar
• LiLChaudhuriAChantJTangZPADGE: analysis of heterogeneous patterns of differential gene expressionPhysiol Genomics200732115415917925482
   PubMedGoogle Scholar
• AlterOBrownPOBotsteinDGeneralized singular value decomposition for comparative analysis of genome-scale expression data sets of two different organismsProc Natl Acad Sci U S A200310063351335612631705
   PubMedGoogle Scholar
• TibshiraniRHastieTNarasimhanBChuGDiagnosis of multiple cancer types by shrunken centroids of gene expressionProc Natl Acad Sci U S A200299106567657212011421
   PubMed Web of Science ®Google Scholar
• RacilaERacilaDMRitchieJMTaylorCDahleCWeinerGJThe pattern of clinical breast cancer metastasis correlates with a single nucleotide polymorphism in the C1qA component of complementImmunogenetics20065811816465510
   PubMed Web of Science ®Google Scholar
• AllanALGeorgeRVantyghemSARole of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancerAm J Pathol2006169123324616816376
   PubMed Web of Science ®Google Scholar
• de Silva RudlandSMartinLRoshanlallCAssociation of S100A4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancerClin Cancer Res20061241192120016489073
   PubMed Web of Science ®Google Scholar
• AliHRGlontSEBlowsFMPD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytesAnn Oncol20152671488149325897014
   PubMed Web of Science ®Google Scholar
• NathDHartnellAHapperfieldLMacrophage-tumour cell interactions: identification of MUC1 on breast cancer cells as a potential counter-receptor for the macrophage-restricted receptor, sialoadhesinImmunology199998221321910610356
   PubMedGoogle Scholar
• OhnishiKKomoharaYSaitoYCD169-positive macrophages in regional lymph nodes are associated with a favorable prognosis in patients with colorectal carcinomaCancer Sci201310491237124423734742
   PubMed Web of Science ®Google Scholar
• OhnishiKYamaguchiMErdenebaatarCPrognostic significance of CD169-positive lymph node sinus macrophages in patients with endometrial carcinomaCancer Sci2016107684685226991548
   PubMed Web of Science ®Google Scholar
• ShiotaTMiyasatoYOhnishiKThe clinical significance of CD169-positive lymph node macrophage in patients with breast cancerPLoS One20161111e016668027861544
   PubMed Web of Science ®Google Scholar
• ChenJYaoYGongCCCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3Cancer Cell201119454155521481794
   PubMed Web of Science ®Google Scholar